Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 0.57 |
| ▸ | TNF | P01375 | 3/20 | 0.57 |
| ▸ | MAPK12 | P53778 | 7/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | RAF1 | P04049 | 1/20 | 0.53 |
| ▸ | LYN | P07948 | 1/20 | 0.53 |
| ▸ | SRC | P12931 | 1/20 | 0.53 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.53 |
| ▸ | HCK | P08631 | 6/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4088539 | 0.94 | MAPK14 (0.57) | MAPK14TNFMAPK12ABL1RAF1 | |
| SCHEMBL7681657 | 0.88 | MAPK14 (0.57) | MAPK14TNFMAPK12ABL1RAF1 | |
| SCHEMBL4088544 | 0.87 | MAPK14 (0.60) | MAPK14TNFMAPK12ABL1RAF1 | |
| SCHEMBL4092132 | 0.86 | MAPK14 (0.56) | MAPK14TNFMAPK12ABL1RAF1 | |
| SCHEMBL4085911 | 0.85 | MAPK14 (0.53) | MAPK14TNFMAPK12ABL1RAF1 | |
| SCHEMBL4087767 | 0.83 | MAPK14 (0.57) | MAPK14TNFMAPK12ABL1RAF1 | |
| SCHEMBL4092182 | 0.83 | MAPK14 (0.56) | MAPK14TNFMAPK12ABL1RAF1 | |
| SCHEMBL4086241 | 0.82 | MAPK14 (0.61) | MAPK14TNFMAPK12ABL1RAF1 | |
| SCHEMBL4094234 | 0.82 | MAPK14 (0.63) | MAPK14TNFMAPK12ABL1RAF1 | |
| SCHEMBL4093091 | 0.81 | MAPK14 (0.55) | MAPK14TNFMAPK12ABL1RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090017036-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | JUNG BIRGIT | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090017036-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | BDKRB2, EDNRB, GRK5 | MAPK14 74/4885TNF 745/4885MAPK12 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.